Mineralocorticoid signaling in transition to heart failure with normal ejection fraction

Hypertension

Volumn 51, Issue 2, 2008, Pages 289-295

  Shapiro, Brian P ^a   Owan, Theophilus E ^b   Mohammed, Selma ^a   Kruger, Martina ^c   Linke, Wolfgang A ^c   Burnett, John C ^a   Redfield, Margaret M ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Collagen; Diastole; Heart failure; Hypertension

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CONNECTIN; DEOXYCORTICOSTERONE ACETATE; MINERALOCORTICOID;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTICLE; BLOOD PRESSURE; CONSCIOUSNESS; DOG; ECHOCARDIOGRAPHY; EX VIVO STUDY; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART OUTPUT; HEMODYNAMICS; HYPERTENSION; NEPHRECTOMY; NERVE BLOCK; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE;

AGING; ANIMALS; AORTA; ARTERIES; BIOLOGICAL MARKERS; BLOOD PRESSURE; COLLAGEN; DESOXYCORTICOSTERONE; DIASTOLE; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; DOGS; ECHOCARDIOGRAPHY; ELASTICITY; HEART FAILURE; HEART VENTRICLES; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MINERALOCORTICOIDS; MYOCARDIUM; SIGNAL TRANSDUCTION; STROKE VOLUME; SYSTOLE; VASCULAR RESISTANCE; VASOMOTOR SYSTEM; VENTRICULAR FUNCTION, LEFT;

EID: 38549165179     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.099010     Document Type: Article

References (40)

1. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43:317-327.
2. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186:1-20.
3. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-1838.
4. Funder JW. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol. 2005;93:121-125.
5. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, Takeda Y, Yoshida J, Miwa T, Okamoto M, Masuyama T, Nonaka Y, Hori M. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol. 2007;292:R946-R954.
6. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation. 2001;104:467-472.
7. Costello-Boerrigter LC, Boerrigter G, Harty GJ, Cataliotti A, Redfield MM, Burnett JCJ. Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction. Hypertension. 2007;50:481-488.
8. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Stork S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754-1761.
9. Munagala VK, Hart CY, Burnett JC Jr, Meyer DM, Redfield MM. Ventricular structure and function in aged dogs with renal hypertension: a model of experimental diastolic heart failure. Circulation. 2005;111:1128-1135.
10. Shapiro BP, Lam CSP, Patel JB, Mohammed SF, Kruger M, Meyer DM, Linke WA, Redfield MM. Acute and chronic ventricular-atrial coupling in systole and diastole: Insight from an elderly hypertensive model. Hypertension. 2007;50:503-511.
11. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol. 2005;289:H501-H512.
12. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982-1990.
13. Nichols WW, O'Rourke M. McDonald's Blood Flow in Arteries. 3rd ed. Philadelphia, PA: Lea & Febiger; 1990.
14. Liu Z, Brin KP, Yin FC. Estimation of total arterial compliance: an improved method and evaluation of current methods. Am J Physiol. 1986;251:H588-H600.
15. Makarenko I, Opitz CA, Leake MC, Neagoe C, Kulke M, Gwathmey JK, del Monte F, Hajjar RJ, Linke WA. Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res. 2004;95:708-716.
16. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation. 2003;107:139-146.
17. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, O'Donnell CJ, Musone SL, Camargo AL, Drake JA, Levy D, Hirschhorn JN, Vasan RS. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension. 2007;49:846-856.
18. Skott O, Uhrenholt TR, Schjerning J, Hansen PB, Rasmussen LE, Jensen BL. Rapid actions of aldosterone in vascular health and disease-friend or foe? Pharmacol Ther. 2006;111:495-507.
19. Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol. 2006;290:H286-H294.
20. Ahokas RA, Sun Y, Bhattacharya SK, Gerling IC, Weber KT. Aldosteronism and a proinflammatory vascular phenotype: role of Mg2+, Ca2+, and H2O2 in peripheral blood mononuclear cells. Circulation. 2005;111:51-57.
21. Titze J, Rittweger J, Dietsch P, Krause H, Schwind KH, Engelke K, Lang R, Kirsch KA, Luft FC, Hilgers KF. Hypertension, sodium retention, calcium excretion and osteopenia in Dahl rats. J Hypertens. 2004;22:803-810.
22. Friedman PA. Codependence of renal calcium and sodium transport. Annu Rev Physiol. 1998;60:179-197.
23. Vanegas V, Ferrebuz A, Quiroz Y, Rodriguez-Iturbe B. Hypertension in Page (cellophane-wrapped) kidney is due to interstitial nephritis. Kidney Int. 2005;68:1161-1170.
24. Laskar SR, Dries DL. The prognostic significance of renal dysfunction in patients with chronic systolic heart failure. Curr Cardiol Rep. 2003;5:205-210.
25. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987-1996.
26. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106:130-135.
27. Villacorta H, Dillmann W. Cardiac hypertrophy-induced changes in mRNA levels for TGF-B1, fibronectin, and collagen. Am J Physiol Heart Circ Physiol. 1992;262:H1861-H1866.
28. Wang W, McClain JM, Zucker IH. Aldosterone reduces baroreceptor discharge in the dog. Hypertension. 1992;19:270-277.
29. Kass DA. Ventricular arterial stiffening: integrating the pathophysiology. Hypertension. 2005;46:185-193.
30. Chen CH, Nakayama M, Nevo E, Fetics BJ, Maughan WL, Kass DA. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol. 1998;32:1221-1227.
31. Garwitz ET, Jones AW. Altered arterial ion transport and its reversal in aldosterone hypertensive rat. Am J Physiol. 1982;243:H927-H933.
32. Jones AW, Hart RG. Altered ion transport in aortic smooth muscle during deoxycorticosterone acetate hypertension in the rat. Circ Res. 1975;37:333-341.
33. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol. 2001;37:662-667.
34. Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997;35:138-147.
35. Neagoe C, Kulke M, del Monte F, Gwathmey JK, de Tombe PP, Hajjar RJ, Linke WA. Titin isoform switch in ischemic human heart disease. Circulation. 2002;106:1333-1341.
36. Bronzwaer JG, Paulus WJ. Matrix, cytoskeleton, or myofilaments: which one to blame for diastolic left ventricular dysfunction? Prog Cardiovasc Dis. 2005;47:276-284.
37. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation. 2005;112:2254-2262.
38. Frenneaux M, Williams L. Ventricular-arterial and ventricular-ventricular interactions and their relevance to diastolic filling. Prog Cardiovasc Dis. 2007;49:252-262.
39. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Cat AN, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-3033.
40. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, Walker F, Zennaro MC, Lombes M. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem. 2001;276:38911-38920.